Treatment outcomes according to extended RAS mutation testing in a phase II study of first-line mFOLFOX plus cetuximab followed by cetuximab in monotherapy as maintenance therapy or mFOLFOX plus cetuximab in patients with metastatic colorectal cancer: The MACRO-2 trial

被引：1

作者：

Aranda, E. ^{[1
]}

Ia-Alfonso, P. Garc ' ^{[2
]}

Benavides, M. ^{[3
]}

Sanchez-Ruiz, A. ^{[4
]}

Guillen-Ponce, C. ^{[5
]}

Safont, M. J. ^{[6
]}

Alcaide, J. ^{[7
]}

Gomez, A. ^{[1
]}

Lopez, R. ^{[8
]}

Manzano, J. L. ^{[9
]}

Mendez-Urena, M. ^{[10
]}

Lopez, C. ^{[11
]}

Garcia-Paredes, B. ^{[12
,13
]}

Gravalos, C. ^{[14
]}

Garcia-Garcia, T. ^{[15
]}

Falco, E. ^{[16
]}

Martin-Valades, J. I. ^{[17
]}

Gonzalez-Flores, E. ^{[18
]}

Navalon, M. ^{[19
]}

Diaz-Rubio, E. ^{[12
,13
]}

机构：

[1] Univ Cordoba, Maimonides Inst Biomed Res IMIBIC, Reina Sofia Hosp,Med Oncol, Spanish Canc Network RTICC,Inst Salud Carlos III, Cordoba, Spain

[2] Gregorio Maranon Hosp, Med Oncol, Madrid, Spain

[3] Hosp Univ Reg & Virgen de la Victoria, Med Oncol, Malaga, Spain

[4] Puerta de Hierro Hosp, Med Oncol, Madrid, Spain

[5] Univ Ramon & Cajal Hosp, Med Oncol, Madrid, Spain

[6] Univ Gen Hosp, Med Oncol, Valencia, Spain

[7] Costa del Sol Hosp, Med Oncol, Malaga, Spain

[8] Hosp Clin Santiago, Med Oncol, Santiago De Compostela, Spain

[9] Germans Trias & Pujol Hosp ICO, Med Oncol, Badalona, Spain

[10] Hosp Mostoles, Med Oncol, Mostoles, Spain

[11] Marques de Valdecilla Hosp, Med Oncol, Santander, Spain

[12] HC San Carlos, Madrid, Spain

[13] Inst Carlos III, Spanish Minist Sci & Innovat, Med Madrid, Ctr Affiliated Red Temat Invest Cooperat RD06 002, Madrid, Spain

[14] Doce Octubre Hosp, Med Oncol, Madrid, Spain

[15] Morales Meseguer Hosp, Med Oncol, Murcia, Spain

[16] Son Llatzer Hosp, Med Oncol, Palma De Mallorca, Spain

[17] Fdn Jimenez Diaz, Med Oncol, E-28040 Madrid, Spain

[18] Virgen de las Nieves Hosp, Med Oncol, Granada, Spain

[19] Complejo Asistencial, Med Oncol, Zamora, Spain

来源：

EUROPEAN JOURNAL OF CANCER | 2015年 / 51卷

关键词：

D O I：

10.1016/S0959-8049(16)31044-9

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2122

引用

页码：S371 / S372

页数：2

共 50 条

[21] CETUXIMAB PLUS MFOLFOX-6 AS FIRST-LINE THERAPY FOR UNRESECTABLE LIVER METASTASIS FROM COLORECTAL CANCER: AN OPEN, NON-RANDOMIZED, MULTICENTER PHASE II CLINICAL TRIAL
Cai, S.
Zhang, W.
Li, W.
Xu, Y.
Gu, W.
Guan, Z.
Cai, J.
Song, C.
Xu, J.
Chi, P.
ANNALS OF ONCOLOGY, 2012, 23 : 217 - 217
[22] Cetuximab plus chemotherapy as first-line treatment for metastatic colorectal cancer: Effect of KRAS mutation on treatment efficacy in Taiwanese patients
Chen, M. C.
Chiang, F. F.
Wang, H. M.
NEOPLASMA, 2013, 60 (05) : 561 - 567
[23] Final analysis of the randomized trial of the German AIO CRC study group: Cetuximab plus XELIRI versus cetuximab plus XELOX as first-line treatment for patients with metastatic colorectal cancer (mCRC).
Moosmann, N.
von Weikersthal, L. Fischer
Vehling-Kaiser, U.
Stauch, M.
Dietzfelbinger, H. F.
Oruzio, D. V.
Klein, S.
Stintzing, S.
Heinemann, V.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[24] A Phase II Trial of FOLFOX6 and Cetuximab in the First-line Treatment of Patients With Metastatic Colorectal Cancer
Boccia, Ralph V.
Cosgriff, Thomas M.
Headley, David L.
Badarinath, Suprith
Dakhil, Shaker R.
CLINICAL COLORECTAL CANCER, 2010, 9 (02) : 102 - 107
[25] Cetuximab observational study as first-line therapy in patients with metastatic colorectal cancer
Itabashi, Michio
Tani, Kimitaka
Muro, Kei
Masuishi, Toshiki
Ohashi, Yasuo
Sugihara, Kenichi
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[26] Cetuximab plus folfiri first-line in metastatic colorectal cancer (MCRC): The randomized phase III crystal trial
Koehne, C.
Zaluski, J.
Chung, Rong C.
Makhson, A.
D'Haens, G.
Pinter, T.
Lim, R.
Ruff, P.
Rougier, P.
Van Cutsem, E.
ANNALS OF ONCOLOGY, 2007, 18 : VII21 - VII21
[27] Maintenance treatment with capecitabine plus cetuximab after first-line standard fluorouracil-based chemotherapy plus cetuximab for patients with RAS wild-type advanced colorectal cancer.
Yuan, Xianglin
Zhao, Ben
Qiu, Hong
Zhang, Mingsheng
Zou, Yanmei
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
[28] RESULTS OF THE USE OF OXALIPLATIN AND CAPECITABINE PLUS CETUXIMAB AS FIRST-LINE THERAPY IN THE TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER: FIRST ANALYSES
Barroso, S.
Sanches, E.
Ferreira, J. M.
Passos, M.
Sa, A.
Nabico, R.
Sotto-Mayor, C.
Santo, J. Espirito
San-Bento, R.
ANNALS OF ONCOLOGY, 2008, 19 : 148 - 148
[29] Results of the use of oxaliplatin and capecitabine plus cetuximab as first-line therapy in the treatment of patients with metastatic colorectal cancer:: First analyses
Barroso, S.
Sanches, E.
Marques, Ferreira J.
Passos, M.
Sa, A.
Nabico, R.
Sottomayor, C.
Espirito, Santo J.
San-bento, R.
ANNALS OF ONCOLOGY, 2008, 19 : 74 - 75
[30] First-line durvalumab plus monalizumab, mFOLFOX6, and bevacizumab or cetuximab for metastatic microsatellite-stable colorectal cancer (MSS-CRC)
Wainberg, Zev A.
Diamond, Jennifer Robinson
Curigliano, Giuseppe
Deva, Sanjeev
Bendell, Johanna C.
Han, Sae-Won
Kalyan, Aparna
Naidoo, Jarushka
Kim, Richard D.
Patel, Sandip Pravin
Kourtesis, Panagiotis
Li, Xia
Ascierto, Maria
Song, Xuyang
Das, Mayukh
Segal, Neil Howard
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)

← 1 2 3 4 5 →